此内容来自:投资组合

Deutsche Bank向Jason Haas构建医疗保健特许经营权

Haas从竞争对手Goldman Sachs加入了Deutsche,他推出了一家致力于专业制药公司的投资银行集团。

A rower since his college days, Jason Haas sees parallels between that pursuit and his chosen profession. “Rowing is all about teamwork,” says Haas, 47, who has been Deutsche Bank’s New York–based head of health care investment banking for the Americas since 2013. “A successful crew must be synchronized, and that’s the key to success in banking too, pulling together resources from across the firm.”

哈斯于2012年加入银行17年后Goldman, Sachs & Co.,他推出了一批服务快速增长和新兴的专业制药公司。Deutsche招募他帮助它赶上他的前雇主和美国银行Merrill Lynch,这是2014年全球和美国医疗保健和美国卫生保健成交量的前两个景点。去年,德意志在美国医疗保健和一年内将五个地方汇总了五个地方,以144亿美元的交易为咨询,而高盛为高盛为2098亿美元。

由于HAAS到达,该公司已将其美洲医疗保健团队从大约35名银行商提升到大约50次,并在几个主要交易中出演,因为该部门经历了兼并和收购的繁荣。2014年,有938名卫生保健并购交易价值30.8亿美元,在全球范围内宣布,历史数量和57%的潮流,超过2013年。一名司机是在与外国竞争对手合并后,药物公司在海外移动他们的总部举行税收负债。

虽然专业pharma deals tend to be relatively small, Haas and his team have been busy. They advised Malvern, Pennsylvania–based Endo Health Solutions, whose products include pain management drugs, on its $1.6 billion acquisition of Canada’s Paladin Labs; the merger, which closed in late 2013, resulted in an Irish domicile for the new company. Last summer Haas represented Auxilium Pharmaceuticals on a $300 million bid for Vancouver’s QLT that would have shifted Auxilium’s headquarters from Chesterbrook, Pennsylvania, to Canada. For Deutsche that led to something much bigger in December, when Auxilium dropped the QLT offer to entertain an unsolicited $2.3 billion bid by Endo. “These re-domiciling deals have given companies the platform to achieve global growth,” Haas says.

作为纽约的家庭州的高山大学本科,哈斯认为是一名医生,但他在1989年赚取金融,赚取国际关系和经济学的学位。哈斯,始终在纽约工作开始joining Citibank’s credit training program; after completing an MBA at Columbia Business School, he moved to Goldman as an associate in 1995. He spent four years in corporate finance before setting up the specialty health care team in 1999.

Haas已经看到若干客户成长为Multibilion-Dollar公司,其中包括rocotaway,基于新泽西的药物制造商华纳Chilcott。当银行支持2004年投资者联合会的投标失败时,他是高盛,以获胜华纳私人。2006年,HAAS属于上市公司的团队,此后由一家团体收购,其中包括J.P. Morgan合作伙伴,纳斯达克股市。三年后,他建议了Procter&Gamble,因为它以31亿美元的价格向华纳销售制药业务。2013年,在转向德意志作为董事总经理后不久,他建议华纳通过都柏林的竞争对手的85亿美元收购Actiavis.

在他的并购外,Haas喜欢帮助公司提高债务和公平。他特别为2008年洛杉矶的美国制药合作伙伴销售到德国Fresenius Se&Co.的一笔交易。这是第一批医疗保健协议使用或有价值右,这是一个根据新公司预计的财务业绩确定价格的金融工具。通过使用这种公开的结构,自送入其他医疗保健兼并的蓝图,美国制药和弗雷斯尼乌斯能够弥合大估值差距。

一名成员?他当地的划船俱乐部,哈斯希望在2015年更加努力,他的高中新生儿子占据了这项运动。As for his Deutsche crew, he believes the bank, which hired two managing directors from Morgan Stanley last year to bolster its health care division, can hold its own against more-established U.S. rivals: “We’re growing our market share as health care has become an increasingly important sector in investment banking.”